ZEISS Medical Ecosystem - Digital Solutions Roll-out

Solid revenue growth in 6M 2022/23 Weaker product mix amid ongoing strategic investment leads to reduced EBIT ZEISS 6M 2022/23 6M 2021/22 855.4 6M 2022/23 € 974.5 million +13.9% ◉ € 143.9 million 6M 2021/22 177.3 6M 2022/23 6M 2021/22 Carl Zeiss Meditec Group 1.44 -18.9% € 1.26 -12.1% Revenue " FX-adj. revenue growth of +12.4% Positive revenue trend in both SBUS and all regions despite continuing supply chain constraints and macroeconomic challenges Open orders of € 573m remain at elevated levels EBIT ◉ ◉ EBIT margin at 14.8% (PY 20.7%) Gross margin improvement from Q1 to Q2 mainly due to sequential recovery in consumables business, though still under PY's level Higher OpEx mainly arising from strategic investments in S&M and R&D growth and innovation initiatives Adj. EBIT margin at 15.3% (PY 21.2%) EPS Lower earnings per share due to reduced EBIT despite positive impact from FX hedging Page 22

View entire presentation